A $10 billion gate is reopening, and the window for certified 8(a) firms is measured in weeks, not months.
The Defense Health Agency (DHA) has confirmed that the OMNIBUS IV Small Business On-Ramp solicitation will drop imminently. This is not a routine procurement. It is a rare opportunity to secure a master contract seat on the Military Health System’s premier research and development vehicle, one that runs through June 2032 and has already generated over $600 million across 51 task orders in roughly three years of activity. For 8(a) executive leadership and capture managers, preparation must be underway now.
The $10B Gate Reopens: Why OMNIBUS IV Is the Priority
OMNIBUS IV is a multiple-award IDIQ supporting military medical research, development, test, and evaluation across the Department of War. The vehicle carries a 10-year ordering period and a $10 billion cumulative ceiling, with a base period running through June 2027 and a five-year option period extending to June 2032. In FY2023, the Medical category team secured a Tier 2 designation for OMNIBUS IV, reflecting its ability to be leveraged across the federal government and its role in increasing Spend Under Management.
Task order activity has accelerated significantly. Over $600 million has been obligated across 51 task orders, with 94% issued from FY2024–2026. The pool of ordering agencies has grown to include DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences.
The on-ramp is restricted to 8(a) firms across the four market segments DHA uses to structure procurement: Medical R&D, Regulatory Processes, R&D Support Services, and Translational Science Support. A master contract seat here is not a transaction; it is a decade-long positioning platform inside the Military Health System.
For firms building a defense health portfolio, read iQuasar’s companion analysis: DHA OMNIBUS IV Proposal Support and Federal Health Market Strategy.
The RFO Paradigm — Capturing Mission Value Over Procedural Compliance
The OMNIBUS IV solicitation delay from February into mid-2026 was not bureaucratic drift; it was deliberate. DHA pushed the date to ensure compliance with the FAR Overhaul guidance, adopted by DoD starting February 1, 2026. This makes OMNIBUS IV one of the first major acquisitions to be evaluated under the Revolutionary FAR Overhaul (RFO) framework, and that changes how winning proposals must be written.
The RFO shifts the FAR from a dense, prescriptive rulebook to a more principle-based, outcome-oriented system. It streamlines FAR parts and significantly increases contracting officer discretion. Unless specifically prohibited in the FAR, contracting officers now maintain the discretion to use policies and practices that were previously mandatory, encouraging them to determine what is suitable rather than treating compliance as the measure.
For OMNIBUS IV proposals, this means the evaluation logic has fundamentally shifted. Contracting officers will assess mission value, technical credibility, and warfighter relevance, not simply check compliance boxes. Proposals built around procedural thoroughness without a compelling mission-impact narrative will underperform those that demonstrate how the firm’s capabilities advance military health outcomes.
The practical implication: your technical volume needs an “85 percent solution” orientation, a clear, direct articulation of what your firm delivers for the warfighter, not an exhaustive inventory of regulatory adherence. iQuasar’s analysis of the FAR Simplification Initiative and What It Means for Federal Contractors provides further context on navigating this shift.
The Technical Requirements of OMNIBUS
OMNIBUS IV’s main goal is to transition findings and innovations from the R&D phase into medical practice, particularly in combat casualty care. The four market segments define the technical terrain:
- Medical R&D: Core research across infectious disease, genomics, radiation health, and chemical and biological readiness
- R&D Support Services: Administrative, IT, scientific and technical, logistics, medical supplies, and facilities support for research programs
- Regulatory Processes: Navigating FDA and DoD regulatory pathways for transitioning laboratory findings to deployable medical products
- Translational Science Support: The critical bridge between lab research and field deployment, converting research outputs into clinical or operational use
The newest and most strategically important expansion area is translational science. This is where DHA is prioritizing investment: the lifecycle from research discovery through regulatory clearance to deployed medical capability. Firms competing in this segment must demonstrate not just R&D depth, but the operational infrastructure to manage regulatory transitions and scaled deployment.
Navigating the Hegseth Compliance Review — Defending the 8(a) Seat
The OMNIBUS IV opportunity arrives in the most scrutinized environment for 8(a) contractors in the program’s history.
On January 16, 2026, Secretary of War Pete Hegseth announced a comprehensive review of 8(a) contracts. The review assesses two primary areas: whether contracts contribute to military readiness and lethality, and whether 8(a) firms are performing contracted work themselves rather than operating as intermediaries. Hegseth ordered a line-by-line review of every small-business, sole-source, and 8(a) contract over $20 million, and indicated that smaller contracts would be examined as well.
For contracts not terminated in the first phase, a secondary review examines performance data, including invoice and payment records, COR logs, points of contact information, and contract deliverables, and any evidence of non-compliant subcontracting is referred to the Inspector General, SBA, and, potentially, DOJ.
For firms pursuing the OMNIBUS IV on-ramp, this review environment has direct strategic implications. Your proposal must do two things simultaneously: win a competitive evaluation and pre-empt the compliance questions a future reviewer will ask. Every pass-through arrangement, every subcontracting structure, every teaming agreement must be documented with a clear rationale for why the 8(a) prime is genuinely performing the substantive work and delivering verifiable mission value.
“Mission necessity” is now both an evaluation criterion and a survival standard. Build it into your proposal from the first page.
The Path Forward — Stress-Testing Your Proposal Before the Deadline
The imminent deadline requires that your submission is technically complete, RFO-compliant, and compliance-hardened all at once. Use this three-step readiness check:
Step 1: Market Segment Alignment – Confirm that your past performance is directly mapped to the market segment(s) you are pursuing. OMNIBUS IV evaluators will assess relevance tightly. Broad capability statements without specific, documented analogous experience in DHA’s program areas will not score well under outcome-oriented RFO evaluation logic.
Step 2: Compliance Documentation Audit – Before submitting, conduct an internal audit of your subcontracting structure, subcontracting compliance limitations, and all teaming agreements. Assume every document will be reviewed post-award under the Hegseth framework. If your current structure cannot withstand that scrutiny, restructure it now, not after the award.
Step 3: PIEE Submission Readiness – Proposals will be submitted through the Procurement Integrated Enterprise Environment (PIEE) Solicitation Module. PIEE submissions have specific formatting, file structure, and metadata requirements that differ from standard email or portal submissions. Validate your technical setup, confirm user roles and permissions, and conduct a test upload well in advance of the deadline. A submission error on a vehicle of this value is not recoverable.
Also Read: Top 5 Contract Vehicles to Pursue in 2026
Act Now — The Timeline Is Not Forgiving
OMNIBUS IV is the highest-value 8(a) vehicle opening in the defense health space this decade. The combination of a $10 billion ceiling, a Tier 2 category management designation, a decade of ordering period, and accelerating task order velocity makes a master contract seat here one of the most strategically valuable positions in the federal market.
But the environment has changed. The RFO demands outcome-focused proposals. The Hegseth compliance review demands airtight execution. And PIEE demands technical precision. Firms that treat this as a standard on-ramp submission will fall short on all three dimensions.
iQuasar supports 8(a) firms across the full pursuit lifecycle: capture management, proposal development, cleared recruiting, federal staffing, and contracting compliance consulting. To discuss your scenario Contact iQuasar today.
